Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 46.9% in November

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 5,200 shares, a decline of 46.9% from the November 15th total of 9,800 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 45,100 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright started coverage on shares of Avalo Therapeutics in a report on Thursday, October 24th. They set a “neutral” rating for the company.

Avalo Therapeutics Price Performance

Shares of AVTX traded up $0.12 during mid-day trading on Friday, hitting $9.23. The stock had a trading volume of 189,176 shares, compared to its average volume of 203,906. Avalo Therapeutics has a fifty-two week low of $3.95 and a fifty-two week high of $34.46. The company’s fifty day simple moving average is $11.17 and its two-hundred day simple moving average is $10.84.

Institutional Trading of Avalo Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC grew its position in shares of Avalo Therapeutics by 350.0% during the second quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company’s stock worth $561,000 after acquiring an additional 35,000 shares during the last quarter. Logos Global Management LP bought a new stake in shares of Avalo Therapeutics during the second quarter valued at approximately $6,722,000. Ikarian Capital LLC boosted its position in shares of Avalo Therapeutics by 1,673.0% during the third quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock worth $9,218,000 after buying an additional 915,629 shares during the period. Finally, RA Capital Management L.P. bought a new position in Avalo Therapeutics in the 3rd quarter worth approximately $9,186,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.